Exelixis
EXEL
#2109
Rank
ยฃ5.74 B
Marketcap
ยฃ20.13
Share price
-1.53%
Change (1 day)
15.14%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of June 2024 : ยฃ0.76 B

According to Exelixis's latest financial reports the company has ยฃ0.76 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31ยฃ0.78 B-27.77%
2022-12-31ยฃ1.08 B-0.23%
2021-12-31ยฃ1.08 B22.65%
2020-12-31ยฃ0.88 B37.62%
2019-12-31ยฃ0.64 B18.19%
2018-12-31ยฃ0.54 B89.39%
2017-12-31ยฃ0.28 B-15.67%
2016-12-31ยฃ0.34 B202.11%
2015-12-31ยฃ0.11 B21.5%
2014-12-31ยฃ92.68 M-36.87%
2013-12-31ยฃ0.14 B-42.3%
2012-12-31ยฃ0.25 B103.58%
2011-12-31ยฃ0.12 B18.21%
2010-12-31ยฃ0.10 B-16.43%
2009-12-31ยฃ0.12 B-30.48%
2008-12-31ยฃ0.18 B33.81%
2007-12-31ยฃ0.13 B48.91%
2006-12-31ยฃ91.32 M5.96%
2005-12-31ยฃ86.19 M6.54%
2004-12-31ยฃ80.9 M-39.48%
2003-12-31ยฃ0.13 B-3.44%
2002-12-31ยฃ0.13 B-11.84%
2001-12-31ยฃ0.15 B108.25%
2000-12-31ยฃ75.41 M1665.95%
1999-12-31ยฃ4.27 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
ยฃ2.87 B 276.67%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ5.55 B 626.96%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ8.65 B 1,033.13%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ5.06 B 563.97%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ7.08 B 828.24%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ19.41 B 2,442.42%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ5.41 B 608.68%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ21.6 M-97.17%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ58.97 M-92.28%๐Ÿ‡บ๐Ÿ‡ธ USA